-
公开(公告)号:US20240344129A1
公开(公告)日:2024-10-17
申请号:US18631875
申请日:2024-04-10
申请人: Karen Anderson , Oliver Kask , Mark Knappenberger
发明人: Karen Anderson , Oliver Kask , Mark Knappenberger
IPC分类号: C12Q1/6881
CPC分类号: C12Q1/6881 , C12Q2600/16
摘要: Disclosed herein are compositions and methods for performing haplotype typing. The compositions comprise nucleic acid primers for amplifying and barcoding HLA loci DNA for multiplex sequencing.
-
公开(公告)号:US20240301491A1
公开(公告)日:2024-09-12
申请号:US18180400
申请日:2023-03-08
申请人: VosBio, Inc.
IPC分类号: C12Q1/6881 , A61B5/097 , C12Q1/6844
CPC分类号: C12Q1/6881 , A61B5/097 , C12Q1/6844
摘要: Breath liquid particles and vapor are captured in a device presenting a surface and chamber space that condenses or freezes the vapor and aerosol particulates. One or more breaths are exhaled through the device. Capture can be performed on the freezing surface immobilizing water upon contact. The chamber space within the device may freeze or condense liquid breath particles and vapor to collect them. After collection, the liquid is gathered and collected either by draining, scraping, pushing, or centrifugal force. The liquid may be collected and combined with a sample preparation reagent such as a virus lysing reagent, an internal standard, etc. After collection, the sample is separated into a plurality of independently analyzable units for detection and quantification of a target. Analysis may be performed by PCR, qPCR RT-PCR, RT-qPCR, LAMP, RPA or any nucleic acid detection method, lateral antigen mass spectrometry, spectrophotometry or any analytical tool or method. Nucleic acid amplification reagents may contain a lysing reagent such as acetonitrile.
-
公开(公告)号:US20240301093A1
公开(公告)日:2024-09-12
申请号:US18569673
申请日:2022-06-14
发明人: David ZHANG , Ping SONG , Omid VEISEH , Siavash PARKHIDEH , Sudip MUKHERJEE , Maria Isabel RUOCCO , Boram KIM , Michael David DOERFERT , Yuxuan CHENG
IPC分类号: C08B37/00 , A61K9/48 , A61K35/39 , A61K35/51 , A61L27/34 , A61L27/38 , A61L29/08 , C12Q1/6881
CPC分类号: C08B37/0084 , A61K9/4816 , A61K35/39 , A61K35/51 , A61L27/34 , A61L27/3804 , A61L29/085 , C12Q1/6881 , A61L2400/02
摘要: Disclosed herein are compounds of the formula: A-L-R1(I), wherein the these variables are defined herein, as well as medical devices comprising said compounds. The present disclosure also provides pharmaceutical compositions comprising the compounds or medical devices disclosed herein. Further, the present disclosure provides methods of treatment using the compounds, medical devices, or pharmaceutical compositions disclosed herein.
-
公开(公告)号:US12071458B2
公开(公告)日:2024-08-27
申请号:US17530456
申请日:2021-11-18
发明人: Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号: A61K39/00 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/569 , G01N33/574 , A61K35/12 , A61K38/00
CPC分类号: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C12N5/0636 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57449 , G01N33/57492 , A61K2035/124 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12Q2600/158 , G01N2333/70539
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20240279720A1
公开(公告)日:2024-08-22
申请号:US18291091
申请日:2022-07-25
IPC分类号: C12Q1/6827 , A61K45/06 , C12Q1/6881
CPC分类号: C12Q1/6827 , A61K45/06 , C12Q1/6881 , C12Q2600/154 , C12Q2600/156
摘要: A method of detecting donor cell death in a subject receiving foreign biological material from a donor. The method comprises sequencing cfDNA in a biospecimen from the subject; determining cellular origin of the cfDNA by identifying methylation patterns in the sequence of the cfDNA and comparing the methylation patterns in the sequence of the cfDNA to known methylation patterns associated with different cell types; and determining source origin of the cfDNA by genotyping the cfDNA and identifying whether the cfDNA originates from the foreign biological material or from the subject. Cell death is detected when the cfDNA has both a cellular origin of the type of foreign biological material that was received from the donor, and a source origin of the donor.
-
公开(公告)号:US20240271188A1
公开(公告)日:2024-08-15
申请号:US18614496
申请日:2024-03-22
发明人: Howard Slater
IPC分类号: C12Q1/6827 , C12Q1/6806 , C12Q1/6816 , C12Q1/6881
CPC分类号: C12Q1/6827 , C12Q1/6806 , C12Q1/6816 , C12Q1/6881 , C12Q2537/16
摘要: Methods of measuring chimerism in a biological sample use informative copy number variations (CNV) in genetically distinct cell populations. Chimerism describes the co-existence of cells originating from more than one individual. Assessing CNV polymorphisms in genomic DNA provides a useful in-vitro method of measuring chimerism. The accuracy of the methods can be validated using an internal validation step.
-
公开(公告)号:US12060610B2
公开(公告)日:2024-08-13
申请号:US14089517
申请日:2013-11-25
申请人: iRepertoire, Inc.
发明人: Jian Han
IPC分类号: C12Q1/6883 , C12Q1/686 , C12Q1/6869 , C12Q1/6881
CPC分类号: C12Q1/6883 , C12Q1/686 , C12Q1/6869 , C12Q1/6881 , C12Q2600/16 , C12Q1/686 , C12Q2549/119 , C12Q2537/143 , C12Q2525/155 , C12Q1/6869 , C12Q2549/119 , C12Q2531/113 , C12Q2525/155
摘要: Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.
-
公开(公告)号:US20240254658A1
公开(公告)日:2024-08-01
申请号:US18593788
申请日:2024-03-01
申请人: 10x Genomics, Inc.
IPC分类号: C40B30/04 , C07K14/74 , C12N15/10 , C12N15/11 , C12N15/85 , C12Q1/6804 , C12Q1/6806 , C12Q1/6818 , C12Q1/6827 , C12Q1/6881 , C40B50/06 , C40B70/00 , G01N33/50 , G01N33/53 , G01N33/532 , G01N33/543 , G01N33/548 , G01N33/569 , G01N33/58
CPC分类号: C40B30/04 , C07K14/70539 , C12N15/1037 , C12N15/1055 , C12N15/1065 , C12N15/1075 , C12N15/11 , C12N15/85 , C12Q1/6804 , C12Q1/6806 , C12Q1/6818 , C12Q1/6827 , C12Q1/6881 , G01N33/5032 , G01N33/505 , G01N33/5304 , G01N33/5306 , G01N33/5308 , G01N33/532 , G01N33/54306 , G01N33/54366 , G01N33/548 , G01N33/56977 , G01N33/58 , C12N2310/20 , C12N2320/10 , C12Q2537/164 , C12Q2563/179 , C12Q2563/185 , C12Q2565/1015 , C40B50/06 , C40B70/00
摘要: Methods and systems are provided for sample preparation techniques and sequencing of macromolecular constituents of cells and other biological materials.
-
公开(公告)号:US12031183B2
公开(公告)日:2024-07-09
申请号:US16226270
申请日:2018-12-19
IPC分类号: C12Q1/6886 , C12Q1/6809 , C12Q1/6881 , G01N33/50 , G16B25/00 , G16B25/10 , G16B40/10 , G16C20/20
CPC分类号: C12Q1/6886 , C12Q1/6809 , C12Q1/6881 , G01N33/5005 , G16B25/00 , G16B25/10 , G16B40/10 , G16C20/20 , C12Q2600/106 , C12Q2600/158 , C12Q1/6809 , C12Q2537/165
摘要: Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.
-
公开(公告)号:US20240218446A1
公开(公告)日:2024-07-04
申请号:US18557408
申请日:2022-04-27
申请人: Mission Bio, Inc.
发明人: Shu Wang , Daniel Mendoza , Benjamin Schroeder
IPC分类号: C12Q1/6881 , C12Q1/6869 , G16B30/00
CPC分类号: C12Q1/6881 , C12Q1/6869 , G16B30/00 , C12Q2600/156 , C12Q2600/16
摘要: Methods described herein are useful for evaluating whether cells, that have previously undergone genetic modification, were successfully modified. Methods for determining whether a cell is a genetically modified cell involves a cell calling step and a dynamic normalization step that takes into consideration the variation of sequencing depth and number of working amplicons. Thus, the disclosed methods are able to more accurately and consistently identify successfully modified cells, even in situations where limited reads are available for analysis.
-
-
-
-
-
-
-
-
-